Latest Breaking News On - Treeline biosciences - Page 2 : comparemela.com

(Loxo Oncology) Josh Bilenker, M.D., and Jeff Engelman M.D., Ph.D., have joined forces to create a new cancer biotech, tapping their combined considerable experience to find new solutions to old oncology research problems. These are big names: Bilenker was until the start of the year Lilly’s cancer R&D chief, put in that position after the Big Pharma ponied up $8 billion for Bilenker’s startup Loxo Oncology two years back. It seems Bilenker wants to get back to biotech and is taking Novartis’ vice president and global head of oncology Engelman, who also directs cancer drug discovery at the Novartis Institutes for BioMedical Research, along with him.

San diegoUnited statesJosh bilenkerJeff engelmanAjax health zeusNovartis institutes for biomedical researchAccess industriesBig pharmaLoxo oncologyNovartis institutesBiomedical researchTreeline biosciencesArch venture partnersசான் டியாகோஒன்றுபட்டது மாநிலங்களில்நோவர்த்திச் நிறுவனங்கள் க்கு உயிர் மருத்துவ ஆராய்ச்சி